BIOMAT Database Logo BIOMAT Database Logo

Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma. 1999

H M Lokhorst, and P Sonneveld, and J J Cornelissen, and P Joosten, and M van Marwijk Kooy, and J Meinema, and H K Nieuwenhuis, and M H van Oers, and D J Richel, and C N Segeren, and G Veth, and L F Verdonck, and P W Wijermans
Department of Hematology, University Hospital Utrecht, The Netherlands.

We performed a phase II study to test the efficacy and feasibility of induction therapy with vincristine, adriamycin and dexamethasone (VAD) and intermediate-dose melphalan, 70 mg/m2 (IDM), to autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma (MM). A total of 77 patients received two cycles of VAD (n = 62) and/or two cycles of i.v. IDM 70 mg/m2 (n = 15) combined with G-CSF. PBSC were harvested after the first IDM, successfully in 87% of patients. Patients with a response to induction received myeloablative therapy with PBSCT (n = 50) followed by IFN maintenance or allo-BMT (n = 11). Seventy-two per cent of patients achieved a response after VAD which increased to 85% after IDM. Of patients who received PBSCT and allo-BMT, 24% and 45% achieved CR, respectively. Toxicity of induction consisted mainly of bone marrow suppression after IDM (median 8 days) with prolonged aplasia in 11% of patients after the second IDM. Only six infections WHO grade 3 occurred during induction. Treatment-related mortality of PBSCT and allo-BMT was 6% and 18%, respectively. Median time of follow-up is 44 months, and 50% of patients after PBSCT and 60% of patients after allo-BMT are still in remission. Survival rates of all patients were 82%, 75% and 63%, and for transplanted patients 86%, 79% and 68% after 12, 24 and 36 months. Well known prognostic factors, including alpha-IFN maintenance after PBSCT, were not significant for response or survival although patients in CR after allo-BMT had a strong tendency for better outcome. VAD/IDM is an effective and safe induction therapy for autologous and allogeneic stem cell transplantation. Based on these observations a phase III trial was started in October 1995 comparing IFN maintenance with PBSCT and allo-BMT after response to induction with VAD and IDM.

UI MeSH Term Description Entries
D008297 Male Males
D008558 Melphalan An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen. Medphalan,Merphalan,Phenylalanine Mustard,Sarcolysine,Sarkolysin,4-(Bis(2-chloroethyl)amino)phenylalanine,Alkeran,L-PAM,Mustard, Phenylalanine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

H M Lokhorst, and P Sonneveld, and J J Cornelissen, and P Joosten, and M van Marwijk Kooy, and J Meinema, and H K Nieuwenhuis, and M H van Oers, and D J Richel, and C N Segeren, and G Veth, and L F Verdonck, and P W Wijermans
Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
February 2012, Annals of hematology,
H M Lokhorst, and P Sonneveld, and J J Cornelissen, and P Joosten, and M van Marwijk Kooy, and J Meinema, and H K Nieuwenhuis, and M H van Oers, and D J Richel, and C N Segeren, and G Veth, and L F Verdonck, and P W Wijermans
A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma.
October 2010, Annals of hematology,
H M Lokhorst, and P Sonneveld, and J J Cornelissen, and P Joosten, and M van Marwijk Kooy, and J Meinema, and H K Nieuwenhuis, and M H van Oers, and D J Richel, and C N Segeren, and G Veth, and L F Verdonck, and P W Wijermans
Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma.
August 2017, Leukemia,
H M Lokhorst, and P Sonneveld, and J J Cornelissen, and P Joosten, and M van Marwijk Kooy, and J Meinema, and H K Nieuwenhuis, and M H van Oers, and D J Richel, and C N Segeren, and G Veth, and L F Verdonck, and P W Wijermans
AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation.
September 2002, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis,
H M Lokhorst, and P Sonneveld, and J J Cornelissen, and P Joosten, and M van Marwijk Kooy, and J Meinema, and H K Nieuwenhuis, and M H van Oers, and D J Richel, and C N Segeren, and G Veth, and L F Verdonck, and P W Wijermans
High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.
January 2018, Bone marrow transplantation,
H M Lokhorst, and P Sonneveld, and J J Cornelissen, and P Joosten, and M van Marwijk Kooy, and J Meinema, and H K Nieuwenhuis, and M H van Oers, and D J Richel, and C N Segeren, and G Veth, and L F Verdonck, and P W Wijermans
Correction: High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.
September 2025, Bone marrow transplantation,
H M Lokhorst, and P Sonneveld, and J J Cornelissen, and P Joosten, and M van Marwijk Kooy, and J Meinema, and H K Nieuwenhuis, and M H van Oers, and D J Richel, and C N Segeren, and G Veth, and L F Verdonck, and P W Wijermans
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency.
August 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
H M Lokhorst, and P Sonneveld, and J J Cornelissen, and P Joosten, and M van Marwijk Kooy, and J Meinema, and H K Nieuwenhuis, and M H van Oers, and D J Richel, and C N Segeren, and G Veth, and L F Verdonck, and P W Wijermans
Chemotherapy of resistant multiple myeloma with vincristine, adriamycin and dexamethasone (VAD).
June 1987, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
H M Lokhorst, and P Sonneveld, and J J Cornelissen, and P Joosten, and M van Marwijk Kooy, and J Meinema, and H K Nieuwenhuis, and M H van Oers, and D J Richel, and C N Segeren, and G Veth, and L F Verdonck, and P W Wijermans
Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma.
June 2018, Blood research,
H M Lokhorst, and P Sonneveld, and J J Cornelissen, and P Joosten, and M van Marwijk Kooy, and J Meinema, and H K Nieuwenhuis, and M H van Oers, and D J Richel, and C N Segeren, and G Veth, and L F Verdonck, and P W Wijermans
High-dose therapy followed by autologous haematopoietic stem cell transplantation in multiple myeloma.
November 2002, Annals of the Academy of Medicine, Singapore,
Copied contents to your clipboard!